Immutep Ltd Asset Resilience Ratio
Immutep Ltd asset resilience ratio. Immutep Ltd (IMM) has an Asset Resilience Ratio of 50.67% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Immutep Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Immutep Ltd (2001–2025)
Asset resilience ratio of Immutep Ltd from 2001 to 2025. This chart shows how Immutep Ltd's Asset Resilience Ratio has changed over time. Read IMM liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Immutep Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Immutep Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$17.26 Million | 10.99% |
| Short-term Investments | AU$62.28 Million | 39.68% |
| Total Liquid Assets | AU$79.54 Million | 50.67% |
Asset Resilience Insights
- Very High Liquidity: Immutep Ltd maintains exceptional liquid asset reserves at 50.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Immutep Ltd Industry Peers by Asset Resilience Ratio
Compare Immutep Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Sinocelltech Group Ltd
SHG:688520 |
Biotechnology | 5.27% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 1.75% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
GH Research PLC
NASDAQ:GHRS |
Biotechnology | 4.73% |
Immutep Ltd Asset Resilience Ratio by Year (2001–2025)
Immutep Ltd asset resilience ratio by year from 2001 to 2025. The table below shows the annual Asset Resilience Ratio data for Immutep Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 50.67% | AU$79.54 Million ≈ $56.28 Million |
AU$156.98 Million ≈ $111.08 Million |
+7.54pp |
| 2024-06-30 | 43.13% | AU$86.94 Million ≈ $61.52 Million |
AU$201.58 Million ≈ $142.63 Million |
+40.70pp |
| 2023-06-30 | 2.43% | AU$3.59 Million ≈ $2.54 Million |
AU$147.45 Million ≈ $104.33 Million |
+2.14pp |
| 2022-06-30 | 0.30% | AU$302.00K ≈ $213.68K |
AU$102.17 Million ≈ $72.29 Million |
-9.80pp |
| 2021-06-30 | 10.10% | AU$8.28 Million ≈ $5.86 Million |
AU$82.03 Million ≈ $58.04 Million |
-18.94pp |
| 2020-06-30 | 29.03% | AU$13.53 Million ≈ $9.57 Million |
AU$46.60 Million ≈ $32.97 Million |
-6.43pp |
| 2014-06-30 | 35.46% | AU$9.00 Million ≈ $6.37 Million |
AU$25.38 Million ≈ $17.96 Million |
+11.08pp |
| 2013-06-30 | 24.38% | AU$8.00 Million ≈ $5.66 Million |
AU$32.81 Million ≈ $23.22 Million |
-26.19pp |
| 2012-06-30 | 50.57% | AU$21.05 Million ≈ $14.89 Million |
AU$41.61 Million ≈ $29.44 Million |
+33.23pp |
| 2011-06-30 | 17.35% | AU$10.00 Million ≈ $7.08 Million |
AU$57.64 Million ≈ $40.78 Million |
-35.25pp |
| 2010-06-30 | 52.60% | AU$10.00 Million ≈ $7.08 Million |
AU$19.01 Million ≈ $13.45 Million |
+40.53pp |
| 2007-06-30 | 12.07% | AU$526.17K ≈ $372.30K |
AU$4.36 Million ≈ $3.08 Million |
-28.43pp |
| 2006-06-30 | 40.50% | AU$2.98 Million ≈ $2.11 Million |
AU$7.36 Million ≈ $5.21 Million |
-39.77pp |
| 2005-06-30 | 80.28% | AU$7.33 Million ≈ $5.19 Million |
AU$9.13 Million ≈ $6.46 Million |
+79.93pp |
| 2004-06-30 | 0.35% | AU$20.00K ≈ $14.15K |
AU$5.77 Million ≈ $4.08 Million |
-0.83pp |
| 2001-06-30 | 1.18% | AU$50.00K ≈ $35.38K |
AU$4.24 Million ≈ $3.00 Million |
-- |
About Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more